Human TBC1 domain-containing kinase is a class I multidomain pseudokinase

This study characterizes full-length human TBCK as a class I multidomain pseudokinase lacking nucleotide binding and canonical catalytic motifs, thereby clarifying its biochemical properties to advance the understanding of TBCK-related encephalopathy.

The Gist

The Big Picture: A Broken Machine Part

Imagine your body is a massive, bustling city. Inside every cell, there are tiny machines that keep the city running. One of these machines is a protein called TBCK.

For a long time, scientists knew that when TBCK breaks, it causes a severe developmental disorder in children called TBCKE. These children struggle with movement, speech, and brain development. However, nobody knew exactly how the TBCK machine worked or why it was breaking. Was it a motor that had stopped spinning? Was it a gear that was stripped? Or was it a part that was never meant to spin at all?

This paper is like a team of mechanics finally taking the TBCK machine apart in a lab to see what's really going on.

The Discovery: The "Fake" Engine

The researchers built a copy of the human TBCK protein in a lab (using insect cells as tiny factories) and studied it closely. They found something surprising:

TBCK is a "Pseudokinase."

To understand this, imagine a car engine.

• Real Kinases are like real engines. They have all the necessary parts (spark plugs, fuel injectors, pistons) to burn fuel and create movement (energy). In biology, they burn a fuel molecule called ATP to power cellular processes.
• TBCK is like a decoy engine. It looks exactly like a real engine from the outside. It has the shape, the casing, and the general layout. But if you pop the hood, you find that the spark plugs are missing, the fuel lines are blocked, and the pistons are glued in place.

The paper confirms that TBCK is a "Class I Pseudokinase." This is a fancy way of saying: "It looks like an engine, but it has no engine parts. It cannot burn fuel."

The Experiments: Testing the Engine

The scientists didn't just guess; they ran three specific tests to prove TBCK is a "fake" engine:

1. The Shape Check (Structure): They looked at the blueprint (using computer models and chemical analysis) and confirmed that TBCK is missing the specific "tools" (motifs) required to grab fuel (nucleotides like ATP) and burn it. It's like a car missing its gas tank.
2. The Stability Test (Heat): They heated the protein up while holding different types of fuel (ATP, GTP, etc.) near it. Usually, if a protein is a real engine, adding fuel makes it more stable and heat-resistant (like oil cooling an engine). But TBCK didn't care. Adding fuel didn't change its temperature stability at all. This proved it has no place to hold the fuel.
3. The Activity Test (Running): They tried to see if TBCK could actually burn fuel (hydrolyze ATP). They set up a race where a real engine (a control protein) was supposed to run. The real engine ran fast. TBCK? It stood perfectly still. It produced zero energy.

Why Does This Matter?

You might ask, "If TBCK is broken and can't do its job, why do we have it? And why does breaking it cause disease?"

This is the most interesting part. Even though TBCK is a "fake" engine, it's not useless.

• The "Scaffolding" Analogy: Imagine a construction site. You have a crane (a real kinase) that lifts heavy beams. But you also have a stationary metal frame (TBCK). The frame doesn't lift anything itself, but it holds the crane in place, connects it to the ground, and helps other workers know where to stand.
• The FERRY Complex: The paper mentions TBCK is part of a team called the "FERRY complex." This team acts like a delivery service, moving packages (mRNA) around the cell. TBCK acts as the anchor or the glue that holds this delivery truck together.

The Takeaway:
The disease (TBCKE) happens not because TBCK stopped "burning fuel" (since it never could), but because the structure of the protein is broken. When the shape of this "scaffolding" protein is damaged by genetic mutations, the whole delivery truck falls apart, and the cell can't build or repair the brain properly.

Summary in One Sentence

This paper proves that the TBCK protein is a structural anchor that looks like a fuel-burning engine but is actually a non-functional decoy, and understanding this "fake engine" nature helps scientists figure out how to fix the delivery trucks in the brains of children with this rare disease.

Technical Summary

1. Problem Statement

TBCK-related encephalopathy (TBCKE) is a severe autosomal recessive neurodevelopmental disorder caused by biallelic mutations in the TBCK gene. While TBCK is known to be a critical component of the FERRY complex (involved in mRNA transport and endosomal trafficking), its specific biochemical and biophysical properties remain poorly defined.

• Knowledge Gap: TBCK is predicted to contain a pseudokinase domain, a TBC domain, and a rhodanese-like domain. Bioinformatic analysis suggests the pseudokinase domain lacks canonical catalytic motifs (VAIK, HRD, DFG), implying it is a "class I" pseudokinase (catalytically inactive). However, many annotated pseudokinases retain unexpected ligand-binding or residual enzymatic activities.
• Objective: To experimentally validate the functional classification of full-length human TBCK, specifically determining if its pseudokinase domain possesses nucleotide-binding capabilities or ATPase/GTPase activity, which is essential for understanding the molecular mechanism of TBCKE.

2. Methodology

The study employed a comprehensive in vitro approach to express, purify, and characterize full-length human TBCK.

• Protein Expression & Purification:
  • System: Full-length human TBCK (UniProt Q8TEA7) was codon-optimized and expressed in Spodoptera frugiperda (Sf9) insect cells using a baculovirus system.
  • Tagging: A TEV-cleavable His-10 tag was added to the C-terminus.
  • Purification: The protein was purified via Ni-NTA affinity chromatography followed by Size-Exclusion Chromatography (SEC) to ensure homogeneity.
• Biophysical Characterization:
  • Mass Spectrometry: Limited proteolysis with pepsin followed by LC-MS/MS was used to map peptide coverage and identify flexible or structured regions.
  • Circular Dichroism (CD): Used to determine secondary structure composition and monitor thermal unfolding to calculate the melting temperature ($T_m$).
  • Differential Scanning Fluorimetry (DSF): Used to assess thermal stability in the presence of various ligands (ATP, GTP, ADP, GDP, MgCl$_2$, and phosphate) to detect nucleotide binding.
• Enzymatic Activity Assays:
  • ATPase/GTPase Assay: A continuous, coupled enzymatic assay (EnzChek Pyrophosphate Assay) was used to detect the hydrolysis of ATP or GTP by monitoring phosphate production in real-time via absorbance at 360 nm.

3. Key Results

• Protein Quality and Structure:

  • Purified TBCK was confirmed as a monomeric species with an apparent molecular weight of ~103 kDa via SEC.
  • LC-MS/MS analysis achieved 78.2% sequence coverage, with two specific regions (residues 227–237 in the pseudokinase domain and 660–680 in the TBC domain) showing reduced coverage, likely due to structural flexibility or protection.
  • CD spectroscopy revealed a predominantly $\alpha$-helical structure (64.8% helix) with a melting temperature ($T_m$) of 47.31 °C.

• Ligand Binding Analysis (DSF):

  • No Stabilization Observed: The addition of MgCl$_2$, ATP, GTP, ADP, GDP, or inorganic phosphate at concentrations up to 10 mM did not significantly alter the thermal stability ($T_m$) of TBCK.
  • Changes in $T_m$ were within experimental error ($\pm$ 1 °C), indicating that TBCK does not bind these nucleotides or divalent cations with high affinity under the tested conditions.

• Enzymatic Activity:

  • No Hydrolysis: The coupled activity assay showed no detectable ATPase or GTPase activity for TBCK. Unlike the positive control (human asparagine synthetase), TBCK failed to produce inorganic phosphate from ATP or GTP.

4. Key Contributions

• First Biochemical Characterization: This study provides the first successful expression, purification, and comprehensive biophysical characterization of full-length human TBCK.
• Definitive Classification: The authors provide experimental evidence confirming that TBCK is a Class I pseudokinase. It lacks nucleotide binding and catalytic activity, validating bioinformatic predictions regarding the absence of VAIK, HRD, and DFG motifs.
• Methodological Framework: The establishment of a robust protocol for producing soluble, monomeric TBCK enables future structural studies (e.g., crystallography, cryo-EM) and functional assays of disease-associated mutants.

5. Significance

• Mechanistic Insight into Disease: By confirming TBCK is catalytically inactive as a kinase, the study shifts the focus of TBCKE research away from kinase inhibition/activation and toward the roles of its auxiliary domains (TBC and rhodanese-like) and protein-protein interactions within the FERRY complex.
• Therapeutic Implications: Understanding that TBCK functions as a scaffold or regulatory protein rather than an enzyme helps refine the search for therapeutic strategies. It suggests that disease-causing mutations likely disrupt structural integrity, protein complex assembly (e.g., FERRY complex formation), or interactions with Rab5A, rather than disrupting a catalytic site.
• Foundation for Future Research: The biophysical baseline established here is critical for interpreting how specific pathogenic variants (over 900 reported) affect protein stability, folding, and function, ultimately aiding in the development of targeted diagnostics and therapies for TBCK-related disorders.